AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Gore enrolls 1st patient in its REVISE clinical study
By OMAR FORD
Medical Device Daily Staff Writer
Nearly 300 patients are subject to take part in the W.L. Gore (Flagstaff, Arizona) REVISE clinical study, which started earlier this month.
According to the company, the study is a randomized, multi-center trial used to establish the efficacy and safety of the Gore Viabahn Endoprosthesis with Propaten Bioactive Surface to revise arteriovenous (AV) grafts at the venous anastomosis in hemodialysis patients.
The study randomizes patients to the Gore Viabahn Endoprosthesis with Propaten Bioactive Surface and to percutaneous transluminal angioplasty (PTA). The study is expected to have up to 280 subjects, with 140 subjects in each treatment arm spread out over 30 sites. It is slated to be completed in 2012.
"This study will provide the clinical community with valuable data on the performance of this heparin-bonded stent graft for AV graft revisions, rather than PTA alone," said Andrew Nish, MD. "The study is designed to show any difference in time between interventions when using stent grafts to treat venous outflow stenoses."
Source: HighBeam Research, Gore enrolls 1st patient in its REVISE clinical study.(Clinical...